1
|
Illes P. Modulation of transmitter and hormone release by multiple neuronal opioid receptors. Rev Physiol Biochem Pharmacol 2005; 112:139-233. [PMID: 2573137 DOI: 10.1007/bfb0027497] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
2
|
Dudás B, Merchenthaler I. Close anatomical associations between β-endorphin and luteinizing hormone-releasing hormone neuronal systems in the human diencephalon. Neuroscience 2004; 124:221-9. [PMID: 14960353 DOI: 10.1016/j.neuroscience.2003.11.021] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/06/2003] [Indexed: 11/24/2022]
Abstract
Endogenous opiates, such as beta-endorphin, inhibit the release of luteinizing hormone (LH) release in the pituitary gland of several species including rat, pig, sheep, and human. Although it is generally believed that beta-endorphin influences gonadal functions via the regulation of hypothalamic LH-releasing hormone (LHRH) release, the morphological substrate underlying this regulation in humans remains elusive. In the present series of experiments the beta-endorphin-immunoreactive (IR) and LHRH-IR neural elements, utilizing single label immunohistochemistry, were mapped. Following the superimposition of the maps of these systems, the overlapping sites were identified and examined in order to verify the putative juxtapositions between the beta-endorphin-IR and LHRH-IR structures. LHRH-IR elements were detected mainly in the medial basal hypothalamus, in the medial preoptic area and along the diagonal band of Broca. Beta-endorphin-IR perikarya were observed in the infundibular region/median eminence, whereas beta-endorphin-IR axon varicosities were detected periventricularly in the preoptic and tuberal regions, in the medial basal hypothalamus and around the mamillary bodies. Careful examination of the immunoreactive elements in the overlapping areas revealed close contacts between beta-endorphin-IR and LHRH-IR structures, which have been verified in semithin plastic sections. These putative beta-endorphin-LHRH juxtapositions were most numerous in the medial preoptic area and in the infundibulum/median eminence of the human diencephalon. In conclusion, the present paper is the first study that revealed close juxtapositions between the beta-endorphin-IR and LHRH-IR neural elements in the human diencephalon. These beta-endorphin-LHRH contacts may be functional synapses, and they may be the morphological substrate of the beta-endorphin control on gonadal functions in man.
Collapse
Affiliation(s)
- B Dudás
- Lake Erie College of Osteopathic Medicine, Erie, PA 16509, USA
| | | |
Collapse
|
3
|
Lal P, Rajeshwari Devi RK. Effect of chronic naloxone and morphine treatments on testicular, body weight, and plumage pigmentation cycle of lal munia, Estrilda amandava. Gen Comp Endocrinol 1997; 107:2-11. [PMID: 9208301 DOI: 10.1006/gcen.1997.6882] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
At Imphal (24 degrees 44' N) testes of lal munia, Estrilda amandava, began in June/July, peaked in September/ October, and thereafter declined to a minimum in December/January. Daily im treatments of 2.5-10 mg/kg/ bird/30 days of naloxone during progressive phase suppressed testicular growth, but without effects during quiescent, peak, and regression phases. Daily morphine (5 mg/kg/bird) during progressive and peak phases stimulated testicular growth, but without effects during quiescent and regression phases. Daily morphine (10 mg/kg/bird) during progressive phase stimulated the testes, an effect reversed by daily im treatments of an equivalent dose of naloxone. Seasonal changes in body weight closely correlated with testicular size. Daily im naloxone (5 and 10 mg/kg/bird/30 days) during progressive phase inhibited the increased body weight, but had no effects during quiescent, peak, and regression phases. Morphine (5 mg/kg/bird/day) during progressive and peak phases increased body weight, but had no effects during quiescent and regression phases. Morphine (10 mg/kg/bird/day) during progressive phase increased body weight, an effect which was reversed by equivalent dose of naloxone. Plumage color increased progressively between May and August/September, was maintained during October, and thereafter declined to reach dull-brown henny feathers by December. Daily im naloxone (2.5-10 mg/kg/bird/30 days) regardless of the reproductive states did not affect plumage color cycle. Morphine (5 mg/kg/ bird/day) accelerated plumage pigmentation between June and August, but had no effect during progressive or peak phases. Postnuptial decline in plumage color was inhibited by morphine (5 and 10 mg/kg/bird/day) and naloxone failed to reverse this effect. It is concluded that in the lal munia, endogenous opioid peptides are important constituents of the neuroendocrine mechanisms that influence development of the testes and body weight.
Collapse
Affiliation(s)
- P Lal
- Department of Life Sciences, Manipur University, Canchipur, Imphal, India
| | | |
Collapse
|
4
|
Molnár J, Halász B. Mesencephalic sites of action of an enkephalin analogue (D-Met2, Pro5)-enkephalinamide and naloxone on the anterior pituitary of male rats. Brain Res 1991; 563:270-2. [PMID: 1786539 DOI: 10.1016/0006-8993(91)91543-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
(D-Met2, Pro5)-Enkephalinamide and naloxone injected into the dorsal raphe nucleus affected luteinizing hormone (LH) and prolactin (PRL) release. Drugs given into the reticular tegmental nucleus and dorsal part of the periaqueductal gray matter induced a PRL response and their administration into the central superior midbrain raphe nucleus caused changes in growth hormone (GH) secretion. The inferior colliculus and the lateral part of the periaqueductal gray matter were ineffective sites.
Collapse
Affiliation(s)
- J Molnár
- Second Department of Anatomy, Semmelweis University of Medicine, Budapest, Hungary
| | | |
Collapse
|
5
|
Johnson JH, Kitts CS. Analysis of neurotransmitter receptors mediating changes in LH release induced by electrical stimulation of the dorsal raphe nucleus in the rat. J Neurosci Res 1991; 29:520-6. [PMID: 1665188 DOI: 10.1002/jnr.490290412] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We report studies of neurotransmitter and receptor species mediating the inhibition of LH release in ovariectomized (OVX) rats and stimulation in OVX estrogen-primed rats induced by electrical stimulation of the dorsal raphe nucleus (DRN). Attempts were made to block effects of stimulation of the DRN in groups of four to nine ovariectomized rats with or without priming with estradiol benzoate (EB) by pretreatment with the 5HT receptor antagonists ketanserin, methysergide, or metergoline; the alpha-adrenergic antagonist phenoxybenzamine; or the opiate antagonist naltrexone. Blood samples were collected via jugular cannulae from the unanesthetized rats at 10-min intervals before and during electrical stimulation of the DRN, and assayed by double antibody radioimmunoassay for LH. To test the effect of stimulation, data from animals in each treatment group were subjected to analysis of variance to obtain the contrast matrix including prestimulation and stimulation time points of interest. The contrast matrix was then used to construct an F ratio and thereby to evaluate the level of significance. In unprimed OVX rats the sustained decrease in plasma LH concentration during stimulation was prevented in rats pretreated with ketanserin or phenoxybenzamine. Methysergide pretreatment delayed the inhibitory effect of DRN electrical stimulation for 30 min, whereas metergoline and naltrexone were ineffective. In EB-primed animals the increase in plasma LH observed during stimulation was prevented in rats pretreated with metergoline, and reversed in those receiving naltrexone. Ketanserin limited the duration of the increase to 10 min, while phenoxybenzamine and methysergide had no significant effect.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J H Johnson
- Department of Anatomy, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298
| | | |
Collapse
|
6
|
Molnár J, Marton J, Halász B. Central nervous system sites of action of an enkephalin analogue, (d-met, pro)-enkephalinamide, and naloxone on the secretion of five anterior pituitary hormones of male rats. J Neuroendocrinol 1990; 2:477-83. [PMID: 19215377 DOI: 10.1111/j.1365-2826.1990.tb00436.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Abstract Central nervous system sites of action of opioid peptides on pituitary hormone secretion were investigated. One nmol of an enkephalin analogue, (D-Met(2), Pro(5))-enkephalinamide, and 10 nmol of the opiate antagonist naloxone were injected into ten different regions of the brain of conscious male rats and their effect on the release of five anterior pituitary hormones tested. The injections were made through a special injection cannula which was inserted into the brain through a guide cannula fixed on the skull and implanted into the brain 5 to 7 days earlier. Both compounds injected into the medial septum, medial preoptic area and hypothalamic paraventricular nucleus affected prolactin, growth hormone and luteinizing hormone (LH) secretion. The enkephalin analogue stimulated prolactin and growth hormone and inhibited LH release. Naloxone induced the opposite effect. Drugs given into the hypothalamic ventromedial nucleus caused changes in plasma prolactin and growth hormone levels. Enkephalinamide increased and naloxone decreased plasma concentrations of both hormones. Administration of the compounds into the dorsal raphe area resulted in alterations of prolactin and LH release, the analogue caused elevation of prolactin and inhibition of LH release, whereas the opiate antagonist resulted in opposite changes. Only an LH response was obtained from the hypothalamic dorsomedial nucleus and a growth hormone response from the central amygdala. Also in these cases the enkephalin analogue decreased LH and elevated growth hormone plasma levels, and naloxone brought about a rise in LH and a diminution of growth hormone concentration. None of the regions were effective in inducing a clear-cut adrenocorticotrophin or follicle-stimulating hormone response. The parietal cortex, medial amygdala and the dentate gyrus were entirely ineffective sites. The findings suggest that in the brain there are multiple sites of action of opioids on pituitary trophic hormone secretion and the effective sites are not identical in terms of pituitary hormone response.
Collapse
Affiliation(s)
- J Molnár
- Second Department of Anatomy, Semmelweis Medical University, Tuzolto utca 58, H-1094 Budapest, Hungary
| | | | | |
Collapse
|
7
|
Petraglia F, Porro C, Facchinetti F, Cicoli C, Bertellini E, Volpe A, Barbieri GC, Genazzani AR. Opioid control of LH secretion in humans: menstrual cycle, menopause and aging reduce effect of naloxone but not of morphine. Life Sci 1986; 38:2103-10. [PMID: 3086650 DOI: 10.1016/0024-3205(86)90209-2] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
A number of studies have been made on the role played by endogenous opioid peptides in the secretion of LH in humans. However no previous studies have compared the effects of the most potent pharmacological agonist and antagonist, morphine and naloxone, in the same subjects. The present study examined the acute effects of injections of morphine and naloxone on plasma LH levels in 30 healthy subjects (18 women and 12 men). Fertile women were subdivided into follicular (n = 6) and luteal (n = 6) phase groups; the remaining 6 were postmenopausal women. The 12 men were sub-divided in two groups of 6 subjects according to age (24-33 years, and over 60 years). There was a two day interval between injection studies in the same subjects. Morphine significantly decreased plasma LH levels in all groups examined (P less than 0.01). On the other hand, naloxone caused a significant increase in plasma LH levels in fertile women during the luteal phase of the cycle, but not during the follicular phase or in postmenopausal subjects, and in young but not in aged men (P less than 0.01). These results indicate that in humans there is a change in the activity of the opioids regulating LH secretion during the menstrual cycle, after menopause and in aged men and that these may be studied by the use of naloxone. The inability of naloxone under certain conditions to increase LH levels reflects the decreased activity of the endogenous system, while morphine, being active in all the subjects, seems to be less discriminative, at least in physiological conditions.
Collapse
|
8
|
Rasmussen DD. Physiological interactions of the basic rest--activity cycle of the brain: pulsatile luteinizing hormone secretion as a model. Psychoneuroendocrinology 1986; 11:389-405. [PMID: 3550855 DOI: 10.1016/0306-4530(86)90001-6] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The hypothesis of the "basic rest--activity cycle" (BRAC) as an ultradian rhythm of CNS activity which integrates many somatic, visceral, and behavioral functions is supported by a variety of studies which demonstrate similar periodicities in the expression of a remarkable number of critical physiological systems. However, the existence of this BRAC has been supported primarily only by this similarity in cyclicity, and the argument in support of this potentially meaningful CNS oscillator is thus largely inferential. Since resolving consistent temporal relationships between a variety of these apparently otherwise unrelated rhythmic functions would strongly support the hypothesized existence of the BRAC, this article first presents methodology for reliable evaluation of these difficult to analyze interactions. Then, a relationship between rhythmic physical activity and pulsatile luteinizing hormone (LH) secretion is employed as a model interaction which allows analysis of the rhythmicity of the BRAC itself. This BRAC entrainment of pulsatile LH secretion is also utilized as a model to demonstrate how the BRAC may modulate the activity of various physiological functions via relatively direct mechanisms, secondary interactions, or entrainment of tissue with its own intrinsic pacemaker activity. The physiological function of the BRAC is discussed relative to this entrainment of pulsatile LH release.
Collapse
|
9
|
Cicero TJ, Schmoeker PF, Meyer ER, Miller BT. Luteinizing hormone releasing hormone mediates naloxone's effects on serum luteinizing hormone levels in normal and morphine-sensitized male rats. Life Sci 1985; 37:467-74. [PMID: 3894852 DOI: 10.1016/0024-3205(85)90409-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Naloxone produces large increases in serum luteinizing hormone (LH) levels in normal males and females, supporting a role for endogenous opioids (EOP) in the tonic inhibition of LH. Since the antagonist apparently exerts no important effects on the pituitary, the reasonable assumption has been made that it elevates gonadotropin levels by affecting the release of LH-releasing hormone (LHRH) from the hypothalamus. However, at present there is no direct in vivo evidence supporting this widely-held view. In an attempt to directly demonstrate that naloxone increases the secretion of LHRH, and thereby elevates serum LH levels, we examined whether a potent synthetic antagonist of LHRH ( [D-p Glu1, D-Phe2, D-Trp3,6]-LHRH, GPT-LHRH) blocked the effects of naloxone in male rats with a normal response to naloxone and in those with a markedly enhanced sensitivity to the drug induced by a brief period of morphine pellet implantation. Our results demonstrated that GT-LHRH antagonized equipotent doses of LHRH (100 ng/kg) and naloxone (0.5 mg/kg) over a similar time course with approximately the same AD50. Most importantly, however, we showed that the GPT-LHRH produced equivalent, parallel shifts to the right in the dose-response curves for LHRH and naloxone, indicative of competitive inhibition. We also found that GPT-LHRH completely abolished the enhanced response to naloxone's effects on LH which occurs in morphine-pretreated rats. Since we observed no competition between LHRH and naloxone for their binding sites in pituitary or brain, the only viable interpretation of our results is that naloxone increases LH by inducing the release of LHRH.
Collapse
|
10
|
|
11
|
Wiesner JB, Koenig JI, Krulich L, Moss RL. Site of action for beta-endorphin-induced changes in plasma luteinizing hormone and prolactin in the ovariectomized rat. Life Sci 1984; 34:1463-73. [PMID: 6323905 DOI: 10.1016/0024-3205(84)90061-4] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
A number of sites have been hypothesized as loci at which opioid substances act to alter the secretion of luteinizing hormone (LH) and prolactin (PRL) (1-8). The aim of the present study was to determine the site(s) at which the opioid peptide beta-endorphin (beta-END) acts to influence plasma LH and PRL levels in the ovariectomized (OVX) rat. beta-END, administered into the third ventricle of conscious OVX rats fitted with jugular catheters, significantly decreased plasma LH in doses greater than or equal to 50 ng and increased PRL levels at all doses administered (10, 50, 100 and 250 ng) in a dose dependent fashion. To identify possible central nervous system sites of action, 250 ng beta-END was unilaterally infused into various brain sites. Plasma LH was significantly decreased and plasma PRL significantly increased by infusions into the ventromedial hypothalamic area, the anterior hypothalamic area, and the preoptic-septal area. There was no significant effect of beta-END infusions into the lateral hypothalamic area, amygdala, midbrain central gray, or caudate nucleus. When hemipituitaries of OVX rats were incubated in vitro with beta-END (10(-7)M to 10(-5)M), there was no suppression of basal or LHRH-induced LH release, nor was there any alteration of basal PRL release. It is concluded that beta-END acts at a medial hypothalamic and/or preoptic-septal site and not the pituitary, to alter secretion of LH and PRL.
Collapse
|
12
|
Abstract
Opioid peptides are found throughout the central nervous system, and have profound effects on neuroendocrine function. In man, exogenous opiates and opioids elevate circulating prolactin, GH and TSH, and suppress the release of the gonadotrophins and pro-opiocortin-related peptides. However, unlike in other species, there is substantial evidence for a physiological role of endogenous opioids only in the case of the gonadotrophins and ACTH/LPH. Most evidence suggests that LH and FSH are modulated via the hypothalamus or amygdala, where concentrations of opioids and opioid receptors are very high. Endogenous opioids appear to be principally concerned with the frequency-modulated release of GnRH, and this may be important clinically in patients presenting with amenorrhoea. ACTH/LPH are under tonic inhibition by endogenous opioids acting at hypothalamic and/or pituitary levels, and changes in this inhibition may be responsible for the release of these peptides in response to certain forms of stress. It has been reported that the opiate antagonist, naloxone, is clinically useful in paradoxically inhibiting the release of ACTH in patients with Nelson's syndrome, but this requires adequate confirmation. Vasopressin is under biphasic opiate control, but the principal effect is probably opiate-mediated inhibition of vasopressin release. The endogenous ligand for this response is likely to be dynorphin. Suppression of vasopressin release by opiates may become a useful therapy in the treatment of the 'Syndrome of inappropriate ADH'.
Collapse
|